News

Results of Phase III ReMoxTB Clinical Trial Published

Moxifloxacin

Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with moxifloxacin shortened the duration of therapy. In summary, while the regimens with moxifloxacin caused a more rapid decrease in mycobacterial load, moxifloxacin containing regimens did not shorten TB treatment to 4 months as predicted.

For more information on the REMoxTB trial results, see here for the TB Alliance press release.

Related Links

Publication in New England Journal of Medicine

TB Alliance Press Release

TB Alliance Graphic

PanACEA: A new approach to tuberculosis research

Moxifloxacin struggles against current TB Drugs: REMox Trials

Additional Links

REMox TB Consortium

TB Alliance

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...